At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Histologically or cytologically confirmed adenocarcinoma of stomach or gastroesophageal junction
- ✓Locally advanced unresectable or metastatic disease progressed ≤180 days since last treatment
- ✓One or more measurable or nonmeasurable evaluable lesions per RECIST
- ✕Pregnant women
- ✕Nursing women
- ✕Women of childbearing potential unwilling to use adequate contraception
- ✕Co-morbid systemic illnesses or severe concurrent disease interfering with safety/toxicity assessment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04660760Phase 2RecruitingUpdate OverdueUpdated 27mo ago · Completion was 23mo agoRamucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study
In Brief
A Phase 2 clinical trial evaluating Paclitaxel, Quality-of-Life Assessment, and 2 other interventions for Clinical Stage III Gastric Cancer AJCC v8 and 30 related conditions. Currently recruiting, targeting 116 participants across 15 sites.
Signals
Detailed Summary
This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction cancer that has spread to other places in the body (advanced). Ramucirumab may damage tumor cells by targeting new blood vessel formation. Trifluridine/tipiracil is a chemotherapy pill and that may damage tumor cells by damaging their deoxyribonucleic acid (DNA). Paclitaxel may block cell growth by stopping cell division which may kill tumor cells. Giving ramucirumab and trifluridine/tipiracil will not be worse than ramucirumab and paclitaxel in treating gastric or gastroesophageal junction cancer.
Study Details
Timeline
Interventions
Given IV
Complete questionnaires
Given IV
Given PO